Cancer
Combination of Keytruda and Yervoy does not improve cancer survival, MSD trial finds
February 2, 2021Manufacturing and Production Cancer, MSD
A new trial by Merck – known as MSD outside of North America – has found that their lung cancer …
NICE recommends Celgene’s REVLIMID for multiple myeloma
January 27, 2021Research and Development Cancer, Celgene
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment after an autologous stem cell …
MSD’s cancer therapy KEYTRUDA gets EU approval
January 26, 2021Manufacturing and Production Cancer, MSD
MSD, known as Merck in the US and Canada, has received approval from the European Commission (EC) for its anti-PD-1 …
How COVID-19 has affected the oncology drugs market
January 25, 2021Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Cancer
In its disruption to clinical trials and drug supply to patients, the COVID-19 pandemic has impacted the most crucial areas …
FDA approves Exelixis’ cancer drug Cabometyx
January 25, 2021Sales and Marketing Cancer, Exelixis
The FDA has approved Exelixis’ Cabometyx (cabozantinib) for patients with advanced renal cell carcinoma (RCC) as a first-line treatment in …
NICE recommends cutting-edge lymphoma treatment for NHS use
January 19, 2021Manufacturing and Production Cancer, NICE
NHS clinicians in England will be able to consider a cutting-edge cancer treatment for some patients with a form of …
AstraZeneca’s Imfinzi gets EU and UK approval for new dosing option
January 15, 2021Medical Communications AstraZeneca, Cancer, Imfinzi
AstraZeneca’s Imfinzi (durvalumab) has been approved in the EU and the UK for an additional dosing option in locally advanced, …
NICE recommends GSK’s ZEJULA for advanced ovarian cancer
January 15, 2021Medical Communications Cancer, GlaxoSmithKline, NICE
NICE has recommended the use of GlaxoSmithKline’s ZEJULA (niraparib) on the NHS in England for adult women with advanced high-grade …
UroGen and MD Anderson to collaborate on bladder cancer treatment
January 14, 2021Cancer, UroGen Pharma
UroGen Pharma, a biopharmaceutical company dedicated to treating specialty cancers and urologic diseases, and The University of Texas MD Anderson …
BeiGene’s tislelizumab gets China approval for non-small cell lung cancer
January 14, 2021BeiGene, Cancer, tislelizumab
BeiGene Ltd has announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) …
Novartis and BeiGene join forces to develop cancer drug tislelizumab
January 12, 2021Manufacturing and Production BeiGene, Cancer, Novartis
Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene Ltd in major markets outside of China, accelerating …
Boehringer Ingelheim and Enara Bio to collaborate on cancer immunotherapies
January 12, 2021Manufacturing and Production Boehringer Ingelheim, Cancer, Enara Bio
Boehringer Ingelheim and Enara Bio have entered into a strategic collaboration and licensing agreement to research and develop novel targeted …
Promising new treatment for drug-resistant prostate cancer
January 12, 2021Manufacturing and Production Cancer
A new experimental drug could offer a promising treatment strategy for men with advanced, drug-resistant prostate cancer, researchers have said. …
Genentech’s cancer drug gets Breakthrough Therapy Designation from FDA
January 5, 2021Manufacturing and Production Cancer, Genentech
Genentech has announced that tiragolumab, a novel cancer immunotherapy designed to bind to T cell immunoreceptor with Ig and ITIM …
Scientists develop new drug to target KRAS mutations in cancer
January 5, 2021Manufacturing and Production Cancer, Cancer Research UK
In a study funded by Cancer Research UK and Wellcome, scientists have developed a new drug that effectively targets the …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
